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Background: The increase in therapeutic options for juvenile idiopathic arthritis (JIA) has added complexity to
treatment decisions. Shared decision making has the potential to help providers and families work together to
choose the best possible option for each patient from the array of choices. As part of a needs assessment, prior to
design and implementation of shared decision making interventions, we conducted a qualitative assessment of
clinicians’ current approaches to treatment decision making in JIA.
Methods: Pediatric rheumatology clinicians were recruited from 2 academic children’s hospitals affiliated with a
quality improvement learning network, using purposive and snowball sampling. Semi-structured interviews elicited
how clinicians with prescribing authority (n = 10) interact with families to make treatment decisions. Interviews
were audio-recorded and transcribed verbatim. A multi-disciplinary research team used content analysis to analyze
the interview data.
To validate data from individual interviews and enrich our understanding, we presented the interview results to
pediatric rheumatology clinicians attending a learning network meeting (n = 24 from 12 children’s hospitals). We
then asked the clinicians questions to further identify and discuss areas of variation in the decision-making
processes.
Results: Clinicians described a decision-making process in which they, rather than the family or other care team
members, consistently initiated treatment decisions. Initial treatment options presented to families generally
reflected the clinician’s preferred treatment approaches, which differed across clinicians. Clinicians used various
methods to inform families about treatment options and tailor information according to perceptions of a family’s
information needs, level of comprehension or mood (e.g. anxiety). The attributes of medication presented to
families fell into 4 categories: benefits, risks, logistics and family preferences. Clinicians typically included family
members in the decision to initiate JIA treatment after limiting the options to fit the clinical situation and the
clinician’s own preferences. Family members’ preferences were seen as more integral in the decision to stop
treatment after symptom remission.
Conclusions: Decision making about initial JIA treatment appears to be largely driven by clinician preferences.
Family preferences are more likely to be considered for treatment discontinuation. Opportunities exist to develop,
test, and implement tools to facilitate shared decision making in pediatric rheumatology.
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Therapeutic options to treat juvenile idiopathic arthritis
(JIA) have grown in number and complexity. What used
to be a crippling condition is now a manageable though
chronic one. Methotrexate has long been a foundational
treatment for JIA, but there is substantial practice vari-
ation in its use [1-3]. In recent years, a growing number
of other treatments have become available for JIA. Such
treatments may differ in mechanism of action, dosing
interval, mode of administration and safety profile [4].
To address this rapidly changing field, in 2011 the
American College of Rheumatology published the first
recommendations for the initiation of therapeutic agents
for JIA [5]. The level of evidence behind these guidelines
leaves multiple reasonable options, which differ in ways
that matter to families [5,6]. Therefore, even with such
guidelines, there is often a need to personalize treatment
plans based upon unique factors brought to each inter-
action between a prescribing clinician and a patient.
In the face of uncertainty about which treatment is
optimal for a specific patient [7], the decision-making
process may be influenced by clinician training and
practice style, clinician beliefs about the tradeoffs of
safety versus effectiveness, and the stated or assumed
preferences of patients and parents [8]. In the adult
setting, the priorities of rheumatoid arthritis patients
and rheumatologists can differ when making decisions
about care escalation [9]. In pediatrics, many parents of
children being treated for JIA are left with persistent
questions, information needs, long-lasting concerns and
worry about treatment adverse effects [6], suggesting a
need for improved clinician-parent communication.
Moreover, adolescents with JIA who have participated in
treatment decisions often wish their role in the decision
process had been different [10]. Their desire to be involved
in decision making [11,12], may further complicate the
process if their preferences differ from those of their
parents [13].
Shared decision making, in which clinicians and fam-
ilies work together to make treatment decisions, may
help overcome some of these challenges. This process
typically involves clinicians offering options and describ-
ing the risks and benefits, and the patient and/or family
members expressing their preferences and values [14].
This conversation leads to a better understanding of the
relevant factors and shared responsibility for deciding
how to proceed in a manner consistent with family pref-
erences and values [15].
In previous work we elicited parent and adolescent
perspectives regarding the treatment decision making in
JIA [6,10]. However, the clinician perspective was un-
known. Therefore, we undertook a needs assessment
aimed at delineating the current decision making process
in JIA treatment, in order to understand the barriers andfacilitators to shared decision making. The study occurred
within the context of a quality improvement initiative of
the Pediatric Rheumatology Care and Outcomes Improve-
ment Network (PR-COIN) aimed at enhancing shared
decision making around therapeutics for JIA. PR-COIN is
a learning network with a mission to improve the care
delivery and outcomes of patients with JIA [16,17]. PR-
COIN’s approach is to use quality improvement science in
tandem with the improving chronic illness care model
[18]. Central to this model is an enriched partnership of
patients and practice teams to improve patient centered
outcomes through the safe use of therapeutics and delivery
of high quality care.
Methods
Design
We conducted a decision-making needs assessment in 2
steps. First we conducted and analyzed semi-structured
interviews using established qualitative methods. Then
we validated that data and enriched our understanding
by presenting pediatric rheumatology clinicians attend-
ing a PR-COIN learning network meeting with questions
to identify and discuss areas of variation, between clini-
cians, in the decision-making process. The Cincinnati
Children’s Hospital Medical Center Institutional Review
Board approved this study.
Interview sample
Using a combination of purposeful and snowball sampling
[19], we recruited pediatric rheumatology clinicians with
prescribing authority from 2 large, academically-oriented
children’s hospitals affiliated with PR-COIN. Using snow-
ball sampling [19], where individuals identify people
known to them to approach for study participation, we
asked early participants to name fellow clinicians with dis-
parate approaches to working with families. Our overall
goal was to hear about diverse approaches to working with
families. We e-mailed potential participants to introduce
the project and inform them that a study team member
would be calling, unless they declined to participate. A
study team member then called potential participants to
schedule an in-person interview with one of two trained
interviewers (EL, JS). Informed consent was obtained from
all participants. Interviews were audio-recorded for verba-
tim transcription and verified by study staff. Recruitment
continued until information saturation was achieved [19].
Interview structure
A semi-structured interview guide (Additional file 1)
was developed based on adult and pediatric literature
about treatment decision making, research on parents’
experiences with treatment decision making in JIA [6]
and input from pediatric rheumatologists. As interviews
progressed, the major content areas remained constant
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prior interviews. Although several interviewees mentioned
other treatment-related decisions, such as physical therapy
and sports participation, we focused this needs assessment
on decisions about medications. Interviews focused on
understanding the typical decision-making process,
treatment attributes (e.g., side effects, cost, time to im-
provement, etc.) considered during decision making and
the challenges of specific decision-making situations (e.g.,
new diagnosis, poorly controlled symptoms, etc.).Interview data coding and analysis
We used descriptive content analysis for data coding and
analysis [20,21]. After reviewing the initial transcripts, the
research team identified major content categories. Each
interview was then coded by a minimum of 2 members of
the research team. Coders identified interview content
that fit into the major categories, as well as additional con-
cepts that had not been identified in the initial interviews.
Codes were aggregated and compared between coders.
Major differences were resolved through discussion. The
analytic process sought to identify areas of agreement
among interviews, as well as outlying concepts and varia-
tions between participants.Table 1 Interview participants
Age











Certified Nurse Practitioner 2 (20%)
Years in current position
Median (Range) 4.5 years (2–25)Data validation
Validation refers to the process of presenting the inves-
tigators’ findings to the participants or to individuals
with similar characteristics to confirm the findings [20].
We first did this by giving a presentation of the findings
from our interviews to the pediatric rheumatology pro-
fessionals attending a PR-COIN collaborative learning
session. A learning session is a face-to-face meeting of
learning network teams to study quality improvement,
share results, and advance network projects. To identify
and discuss areas of variation in decision-making pro-
cesses, particularly related to the attributes found to
influence decision making during initial interviews, we
constructed multiple choice questions based upon the
interview data (Additional file 2) and used an audience
response system to capture the pattern of responses.
For example, we asked, “How often do you discuss the
magnitude of the expected improvement when starting
or changing mediations: never, rarely, sometimes, al-
most always, always?” Following each question, the
percent choosing each option was displayed graphically
to participants and research team members facilitated a
discussion to better understand the sources of variation
among participants. This process assisted in the or-
ganization of themes from the interviews and confirmed
our results. Results were further validated by inviting
review and feedback on a draft of this manuscript by
both interview and learning session participants.Collectively these groups are referred to as clinicians
throughout this manuscript.Results
Participants
We interviewed a total of 10 clinicians. Most were white,
female and had been in their current position for an
average of 4.5 years (Table 1). Learning session partici-
pants included 24 clinicians from 12 hospitals, of which
21 had prescribing authority. Demographic information
was not collected from learning session participants,
some of whom had also participated in interviews.
Our results are organized according the four major
themes found in our data: clinicians’ decision process,
treatment attributes, working with families to make deci-
sions, and challenges in JIA treatment decisions. Each sec-
tion has a corresponding table with quotations illustrating
the findings.Clinicians’ decision process
All clinicians indicated that the chronicity of JIA leads to
multiple decision points. (Table 2) Moreover, decisions
may recur during the course of treating a patient with JIA.
As one clinician stated, “…down the road, we need to have
a discussion and see how much benefit [the patient’s]
gotten….then it’s just a reassessment.” In considering
medication decisions most clinicians reported they had
a preferred approach to treatment, such as following
published guidelines, step-up therapy, or early aggres-
sive therapy. However, there was wide-variation in
which of these approaches each individual favored.
These individual preferences, in turn, determined the
menu of options presented to families.




“I typically sort of set up a menu of possibilities, all of which are within that evidence-based realm, and I’m fairly
comfortable with choices they make.” Clinician 9
“Well, so in my own mind, I have a certain approach I use… it’s divided up into kind of immediate short-term treatment
and then also treatments that would address long-term disease control.” Clinician 10
“So it all depends on how they present, what phase they get to us, how many joints, how much disability, how much
systemic disease, and then try to be aggressive at first to get the thing under control.” Clinician 12
“…now there’s treatment guidelines, so that makes it easier. I mean, kind of a step-wise approach.” Clinician 14
Timing of Decision “So after diagnosis has been reached I go through the different types of medications that we use to and I usually start by
talking about the more benign medications.” Clinician 2
“A treatment plan can always change … whether it’s side effects or flare-up of disease or something like that or new
medical literature that comes out.” Clinician 3
“If it’s recurrence of disease after a long period of being quiet, you need to know what the family has been through
before…” Clinician 9
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on the timing of the decision: whether the decision occurs
at diagnosis, when symptoms persist despite current treat-
ment, or when a patient has clinical remission on treat-
ment. When initiating treatment for newly diagnosed
children and adolescents, clinicians felt the treatment
discussion was typified by a presentation of the array of
treatment options perceived by the clinician to be the best
choices. In the setting of treatment failure, decision mak-
ing was complicated by the need to distinguish between
ineffective treatment, poor adherence and treatment-
limiting adverse drug reactions. After achieving remission,
“…the attention immediately turns to ‘How do we get off
these things?’”
Treatment attributes
When presenting treatment options to families, the at-
tributes considered by clinicians fell into 4 categories:
benefits, risks, logistics and family preferences. (Table 3)
Treatment benefits included symptom relief, long-term
effectiveness and time to expected improvement. As
one physician stated, in describing a particular patient
encounter, “I wanted to start [a specific medication]




“…what percent would get side effects, percent that appr
“So I usually give them a highlight of the risk and just the
go through all of the minor side effects. And then talk abo
Logistics “Route of administration is a big deal for patients. So, that
“Usually, I will kind of explain that these are the options an
“So I tell parents …. [the patient] could be on this medicin
Family
Preferences
“But it’s their choice, not mine.” Clinician 4
“You’re finding out and trying to understand what would
the medication, what their insurance may or may not pay
effects may be.” Clinician 3all clinicians said they always or almost always discussed
how likely a medication was to work, but there was less
consistency in discussing the expected magnitude of
improvement. In contrast, all clinicians considered the
risks of treatment and discussed side-effects with parents.
Infusion reactions, immunosuppression and malignancy
were specifically mentioned as important side-effects to
discuss.
When choosing options to present to families, most cli-
nicians always or almost always considered logistical as-
pects of the treatment such as the route of administration,
travel needed for infusions, costs, associated lab tests and
the expected length of treatment. However, the specific
logistics considered in each situation varied. For example,
some clinicians, reflecting on their preferred options, felt
that because some treatments only come in one form
there is not always a choice to be made about route of
administration. Finally, clinicians considered patient char-
acteristics such as age, disease severity and the patient’s
psychological and sociocultural context. For example, one
clinician identified “chaotic households where there may
be two parents or an absent parent, parents incarcerated
or…whatever reason” as a particular challenge in treat-
ment decision making.oved, how rapidly they can expect to see improvement.” Clinician 4
major…the ones that have the highest frequency of occurring and I will
ut the benefits.” Clinician 13
certainly is something that really needs to be considered.” Clinician 3
d… what potential cost might be.” Clinician 14
e for a long time.” Clinician 4
work best on them from a treatment standpoint as far as administering
for, what their tolerance or intolerance to the potential specific side
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Many clinicians expressed concern about families experi-
encing information overload. (Table 4) They felt that fam-
ilies’ ability to absorb and retain information is limited,
especially at the time of diagnosis. As one clinician said,
“…they just are in over their heads and they’re feeling very
overwhelmed and you give them a lot of options I think
they get—they just don’t know what to do.” Some try to
meet the anticipated information needs by providing both
verbal and written information.
Many clinicians also had concerns that parents’ fears
of adverse drug reactions may limit “their willingness to
use, maybe, certain medications that I think, perhaps,
would be beneficial.” Others felt that addressing parents’
fears led to families being more open to treatment and
may provide an opportunity to give the family needed
hope and optimism. The concerns about families’ under-
standing of the disease and treatments, fear of adverse
drug reactions and need for hope occurred against a
backdrop in which some clinicians worried that families
do not or cannot tell them what they do not understand.
Overall, descriptions of the decision-making process
largely involved the clinician making a recommendation
and anticipating that the family would accept it. How-
ever, there were situations that led to clinicians altering
their practice, such as families who came to an appoint-
ment with outside information, difficult social situations
or families with particular concerns about treatment.
Likewise, when the evidence was less clear, such as in
deciding when to stop treatment, clinicians were more
likely to actively consider family members’ preferences.
Challenges in JIA treatment decisions
Clinicians highlighted a number of medical and system
challenges to making treatment decisions for children withTable 4 Working with families to make a decision
Sub-themes Supporting quotations
Information Delivery “Some people come and as soon as they hear a diag
then some, the more information you give them the
“I give them data. I show them sheets that have sum
“…some families deal better when you speak in more
educated.” Clinician 2
Parents’ Fears “I find it’s harder to implement the injection therapies
afraid of getting the shot.” Clinician 11
“And then also, when you talk about immunosuppres
have an effect the rest of their lives.” Clinician 2
“They might have apprehensions or things like that re
inherent or an issue with us getting the medications
Giving
recommendations
“Patients aren’t always amendable to what we recom
“In terms of the type of biologics, I generally recomm
is data out there, longer sort of term data.” Clinician 1
“And a lot of times, families say, you know, will ask w
me to put myself in their shoes but I tell them what IJIA. (Table 5) Medical challenges included limited long-
term data for some treatments, the challenge of achieving
disease control while minimizing adverse drug reactions
and long-term risks, and “that we don’t know when it’s
okay to stop these medications.” This last point was
particularly emphasized during the learning session dis-
cussion in which clinicians’ answers about when they
would consider stopping treatment for a patient in re-
mission on medication varied widely. There were also
health care system challenges; the most commonly
mentioned being the cost of treatment and difficulties
obtaining insurance approval. Another system challenge
was ensuring families get consistent information from
all clinicians.
Discussion
Consistent with what is known from parents’ perspectives
[6], our needs assessment revealed a clinician-centered
decision-making process in JIA, including which options
are being considered and the weight given to treatment
attributes. Importantly, however, nearly all clinicians
described situations in which they would alter their
typical process. This suggests a capacity for flexibility
and a willingness to consider other approaches to
treatment decision making. Such flexibility is essential
to PR-COIN’s work to improve shared decision making.
Clinicians’ stated concerns about over-whelming families
with information may be one of the reasons that other
studies, in both JIA [6] and other conditions [22], have
found that families lack desired information. This lack of
desired information is particularly notable since the treat-
ment attributes considered by parents [6] mirror those
highlighted by the clinicians in this study. Alternatively,
due to the different value clinicians and families place on
treatment attributes, the relative amount of informationnosis, they can’t comprehend anything beyond that for that visit and
less anxious they are in those kinds of things.” Clinician 8
marized those risks.” Clinician 9
concrete terms versus other families that, you know, may be more well
when the parents are afraid of giving the shot than when the child is
sant medications and maybe they’re worried about well what’s going to
garding certain or some of the drugs that we use so that can be
that we would prefer a patient to be on…” Clinician 3
mended.” Clinician 3
end etanercept and that is just because we’ve used it a long time, there
3
hat would you do if it were your child. So, I always say it’s very hard for
think I would choose if they ask that.” Clinician 11




“They want to know long-term and as these biologics are coming up quicker and quicker, we don’t have some of that data
yet and so I think that’s challenging for me.” Clinician 4
“…the unknowns about long-term use of these biologics … I think that factors in too, as far as any decision making that you
have. That’s probably the biggest challenge.” Clinician 14
When to stop
treatment
“You’re really worried about whether when you taper, whether there’s going to be a worsening disease, whether you’ll be
able to use the same medications and whether it will be just as effective.” Clinician 13
“One of the questions they always have also is when we stop this medicine which I think is harder to answer because I think
we’re better in medicine, at starting medicines than stopping…” Clinician 11
Health System
Challenges
“I think expenses are a big [challenge], how costly the medication is.” Clinician 9
“…and trying to understand what would work best on them from a treatment standpoint as far as administering the
medication, what their insurance may or may not pay for…” Clinician 3
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needs. This contrast between clinicians’ concerns about in-
formation overload and many families experience of being
under-informed [6] suggests that new methods, such as
decision aids, are needed for assessing and addressing
families’ information needs in pediatric rheumatology.
In adult medicine, numerous studies have addressed
patients’ information needs through the use of decision
aids [23,24]. In addition to addressing information needs,
decision aids may also help ensure that families are in-
cluded, to the extent they desire, in treatment decisions
[23]. Interventions that help develop a two-way flow of in-
formation may be more successful at shifting the decision-
making structure to one that is more family-centered
[25,26], by helping clinicians consider the patient/family
goals and preferences, as well as provide sufficient,
consistent information to families. Changing clinicians’
behavior will be challenging [27,28], However, our needs
assessment revealed opportunities that exist for expanding
shared decision making into pediatric rheumatology. For
areas that currently lack treatment guidelines or where
there is professional uncertainty, such as in treatment de-
intensification, clinicians already describe a more active
role for families. Developing tools [23,24] that channel this
impulse to include families in some decisions is an essen-
tial step towards more broad adaptation of shared decision
making.
To further facilitate such a change, treatment guidelines
could highlight decisions that have multiple medically
reasonable options about which patients and parents
may have differing preferences. Including such prompts
for shared decision making may help alleviate some of
the tension between following guidelines and engaging
in shared decision making. Additionally, such guidelines
could be coupled with decision aids to further facilitate
elicitation of family preferences [29].
Given that little research has focused on pediatric cli-
nicians’ roles in treatment decisions, especially among
sub-specialists, this needs assessment provides import-
ant insight into how such decisions are made but doeshave limitations. Our finding that information saturation
was achieved after the tenth interview was confirmed by
the learning session discussion which revealed no new
topics or treatment attributes. Although we included clini-
cians from 12 institutions in our process of data validation
the generalizability of this work, especially outside of
pediatric rheumatology, may be limited. All clinicians were
aware that this work was conducted as preparation for
implementing shared decision making tools within PR-
COIN. Such knowledge may have influenced the way
clinicians discussed decision making, particularly their
experiences partnering with families. Additionally, al-
though previous work has focused on parents’ [6] and
adolescents’ [10] perspectives on decision making, the study
reported here only includes the clinician perspective.
Based on the findings of this needs assessment, the
authors of this manuscript and collaborators from PR-
COIN are developing a tool to be used during clinic
visits to help structure decision making. This tool, like
others designed to support selecting a medication from
among multiple medications with multiple attributes
[24,30,31], will facilitate consistent information delivery
and spark conversations between clinicians and families.
It will highlight the treatment attributes which providers
and parents considered key to treatment decisions. More-
over, the tool will present the minimum amount of infor-
mation necessary so that clinicians can tailor the depth of
information to individual families’ needs. Importantly,
while this study presents a needs assessment based on in-
terviews with prescribing clinicians, patients and families
will be key partners in assuring our success in developing
a tool to support shared decision making.
Conclusions
Understanding the current decision making process, in
this case in JIA, is an essential step towards developing
methods for improving the quality of medical decisions.
Despite strong evidence of efficacy in adult medicine
[23], the adoption of tools designed to foster shared deci-
sions has been slow in practice settings [32-34]. However,
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of a collaborative learning network and garnering agree-
ment about the potential for benefit of such tools, we an-
ticipate a more rapid adoption of tools in network sites
and an opportunity to measure their impact. In turn, the
adoption of shared decision making tools may lead to im-
proved decision quality and higher value care as chosen
treatments are consistent with patients’ and parents’ well-
informed preferences.
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